An observational study in Hysterectomy, Benign Uterine Diseases, sponsored by Distalmotion SA. Recruiting at 2 sites in United States. Open to female participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Distalmotion SA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Uterine Diseases with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Uterine Diseases · United States.
Among the 17 studies in Uterine Diseases with a site in United States, this one is the only one that started in 2026, is one of 2 observational ones, and was the 17th registered.
73 studies on the registry are indexed under Uterine Diseases; 9 are open to participants now.
Browse Uterine Diseases studies →3 of the 17 studies in Uterine Diseases with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Puerto Rico
Ages 18+ · Women only
NiKang Therapeutics, Inc. · Sites in United States, Korea, Republic of
Ages 19+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Uterine Diseases studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 22 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 1 · Phase 4 2
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 112 is below the median of 135 across 13 observational studies indexed under Uterine Diseases.
Median enrollment 100 across the 15 interventional studies, 124 across the 2 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 17 have an industry lead sponsor. The 10 most frequent:
Distalmotion SA is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Distalmotion SA has 1 study filed under Uterine Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Uterine Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this post-market, observational study is to collect real-world data under anticipated conditions of use that demonstrates that the device performs as intended (accurate, precise control of surgical instruments) in patients undergoing robotic-assisted and laparoscopic hysterectomy for benign disease.
Adult patients undergoing a hysterectomy for benign disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Robotic-assisted and laparoscopic hysterectomy for benign disease with the DEXTER robotic surgery system.
Primary safety outcome
Occurrence of Clavien-Dindo grades III-V adverse events
Time frame: up to 42 days after surgery
Primary efficacy outcome
Successful completion of the DEXTER-assisted procedure, i.e. free of any conversion to an open or fully laparoscopic surgical approach
Time frame: Intraoperative
Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Distalmotion SA